Wegovy vs compounded semaglutide: what is actually different

This comparison is written by the FormBlends editorial team. FormBlends dispenses compounded semaglutide. That is a reason to read the page carefully, and it is also why the page is going to be blunt: compounded semaglutide is not FDA approved, is not interchangeable with Wegovy, and every advantage it has is a practical or financial one rather than an evidential one.

The evidence gap is the whole difference

Everything this site says about what semaglutide does comes from trials of Novo Nordisk's product: 14.9% weight loss in STEP 1, a 20% relative reduction in cardiovascular events in SELECT, the adverse reaction table in the label. A compounded vial borrows all of that on the assumption that its contents are the same peptide at the stated concentration, sterile, and stable to the beyond-use date. Nobody has run a trial to check. FDA's page on unapproved GLP-1s puts the point precisely: it does not review compounded drugs before they are marketed, and it has specific concerns about products made from semaglutide sodium or acetate.

That does not mean any given vial is bad. It means the assurance comes from the pharmacy, its licence, its testing and its transparency, rather than from FDA. The compounding guide lists the questions that transfer that assurance to you.

Dosing is where the risk concentrates

A Wegovy pen cannot be drawn up wrong. A vial can. FDA's adverse event reports include patients who measured incorrect doses and clinicians who miscalculated them. The failure modes are mundane: reading units as milligrams, keeping last month's syringe mark after the concentration changed, choosing a 1 mL syringe for a 5-unit dose. The units converter is built for those errors, and the label's principle still holds: confirm the mark with the dispensing pharmacist before the first draw from every vial.

Escalation is the other risk. The Wegovy label steps up every 4 weeks for a reason: gastrointestinal reactions cluster at each step. FDA reports compounded prescriptions that escalated faster or dosed more often than the label. The titration planner will lay out a compounded schedule only if it matches a label template, and it will not shorten a step for anyone.

What compounding does offer

Two things, and they are real. First, form: a prescriber can write a dose that no pen delivers, which matters for someone who tolerates 1.7 mg but not 2.4 mg and wants something between, or who is on a slower step-down. Second, price and access: NovoCare's $349 self-pay price is the brand floor, and some compounded programmes are below it. Neither of those is a safety argument. Price them second.

Regulatory position after February 2025

FDA's February 21, 2025 declaratory order ended the shortage that had allowed compounders to make copies of Wegovy and Ozempic without triggering the "essentially a copy" restrictions, with wind-down dates of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. Compounding continues under the ordinary rules of sections 503A and 503B, which are about individual prescriptions and clinical need rather than shortage. What a given pharmacy may lawfully dispense to a given patient is a question for that pharmacy and that state; a website cannot answer it.

FormBlends describes its own compounded semaglutide program, including pharmacy sourcing and how vials are labelled, on its product page. Read it with the table above in front of you.